Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:ffda67b2608c4a003406e93ffcc05edb]

Determine the maximum tolerable dose or optimal biological dose of MEDI3617 administered as a single-agent, MEDI3617 co-administered with bevacizumab or weekly paclitaxel monotherapy, or MEDI3617 co-administered with carboplatin plus paclitaxel or carboplatin plus gemcitabine combination chemotherapies in subjects with advanced solid malignances refractory to standard therapy or for which no standard therapy exists

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:ffda67b2608c4a003406e93ffcc05edb]

Determine the maximum tolerable dose or optimal biological dose of MEDI3617 administered as a single-agent, MEDI3617 co-administered with bevacizumab or weekly paclitaxel monotherapy, or MEDI3617 co-administered with carboplatin plus paclitaxel or carboplatin plus gemcitabine combination chemotherapies in subjects with advanced solid malignances refractory to standard therapy or for which no standard therapy exists